Live Breaking News & Updates on ஹீமாட்டாலஜி ஆண்டு சந்தித்தல்

Stay updated with breaking news from ஹீமாட்டாலஜி ஆண்டு சந்தித்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novel Antibody Shows Benefit in Cold Agglutinin Disease


Apr 8, 2021
Treatment increased hemoglobin, decreased fatigue
Results from a small open-label trial suggested that treatment with an investigational humanized monoclonal antibody may be an effective treatment for cold agglutinin disease, a rare autoimmune hemolytic anemia for which there are no approved therapies.
The 26-week, single-group trial tested intravenous sutimlimab in 24 cold agglutinin patients who had recently undergone transfusions and found infusions of the antibody halted hemolysis, increased hemoglobin levels, and reduced fatigue in more than half of patients.
The composite primary endpoint was a “normalization of hemoglobin level to 12 g or more per deciliter or an increase in hemoglobin level of 2 g or more per deciliter from baseline, without red-cell transfusion or medications prohibited by protocol,” Alexander Röth, MD, of the West German Cancer Center, University Hospital Essen, University of Duisburg-Essen in Essen, Germany, and colleagu ....

United States , West German , Peggy Peck , University Of Duisburg , American Society Of Hematology Annual Meeting , University Hospital Essen , German Cancer Center , West German Cancer Center , New England Journal , American Society , Hematology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , மேற்கு ஜெர்மன் , பெக்கி பெக் , அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி ஆண்டு சந்தித்தல் , பல்கலைக்கழகம் மருத்துவமனை எஸெந் , ஜெர்மன் புற்றுநோய் மையம் , மேற்கு ஜெர்மன் புற்றுநோய் மையம் , புதியது இங்கிலாந்து இதழ் , அமெரிக்கன் சமூகம் , ஹீமாட்டாலஜி ஆண்டு சந்தித்தல் ,

Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights


Our six dermatology products are marketed by our partner company, Journey Medical Corporation (“Journey”).
Our products generated net revenues of $44.5 million for full-year 2020, compared to full-year 2019 net revenues of $34.9 million, representing growth of 28%. Our products generated $13.7 million in revenues in the fourth quarter of 2020, compared to $11.1 million in the fourth quarter of 2019, representing growth of 23%. While we generated revenue growth year-over-year in 2020, sales of our products were impacted by the COVID-19 pandemic, which caused a temporary supply shortage and impacted the ability of our sales force to make in person calls, due to states slowly re-opening.
We in-licensed and recently launched our sixth prescription dermatology product. ....

United States , Fred Hutch , Samsung Biologics , Lindsaya Rosenwald , International Symposium On Amyloidosis , American Society Of Hematology Annual Meeting , Prostate Cancer Foundation Scientific , Trademark Office , Committee For Orphan Medicinal Products , European Society For Medical Oncology Virtual Congress , Health Technology Assessments , Madison Pharmaceuticals Inc , Caelum Biosciences Inc , Fred Hutchinson Cancer Research Center Hutch , Society For Immunotherapy Of Cancer , Checkpoint Therapeutics Inc , Jude Children Research Hospital , European Commission , Drug Administration , Journey Medical Corporation , Alexion Pharmaceuticals Inc , Mustang Bio Inc , Neupharma Inc , Zydus Group , European Medicines Agency , Fortress Biotech Inc ,

Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript


Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Cellectis SA (NASDAQ: CLLS)
Operator
Greetings. Welcome to the Cellectis Fourth Quarter and Full-Year 2020 Earnings Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.
At this time, I ll turn the conference over to Simon Harnest, Chief Investment Officer. Simon, you may begin.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to ....

France General , North Carolina , United States , Andre Choulika , Hartaj Singh , Jack Allen , Hartaj Singh Oppenheimer , Wangzhi Li , Gena Wang , Salveen Richter Goldman Sachs , Soumit Roy Jones , Soumit Roy , Ingrid Bensinger , Gena Wang Barclays , Salveen Richter , Yigal Nochomovitz , Ingrid Bensinger Kempen , Nick Abbott , Yigal Nochomovitz Citigroup , Simon Harnest , Wangzhi Li Ladenburg , Samantha Corwin William Blair , Carrie Brownstein , Michael Schmidt Guggenheim , Jean Pierre Garnier , Biren Amin ,